Clinical trials: GIST, active
GIST of Stomach, Gastric Cancer
Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site
Participants with gastrointestinal stromal tumors(GIST) were divided into favorable and unfavorable sites according to the anatomical site of the tumor, and this study aims to validate the overall postoperative morbidity and…
- Conditions
- GIST of Stomach, Gastric Cancer, Surgery, Complication
- Trial name
- NCT03716089
- Testing
- Laparoscopic resection
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fujian Medical University
Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan…
- Conditions
- Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor, Gastrointestinal Stromal Tumors, Ovarian Germ Cell Tumor
- Trial name
- SUR-CAN (NCT05500391)
- Testing
- Oncological Follow-up
- Where
- 3 sites in France
- Volunteers
- 88 people
- Sponsor
- Centre Oscar Lambret
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Small Size Gastrointestinal Stromal Tumors, GIST
RCT of EFTR Versus STER for GIST Treatment
Endoscopic resection has been increasing utilized as the treatment for small size gastrointestinal stromal tumors (GIST), of which the best resection method has not been identified.
- Trial name
- NCT07411118
- Testing
- Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTR, Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTR
- Where
- 4 sites in China, Hong Kong and 2 more
- Volunteers
- 136 people
- Sponsor
- Chinese University of Hong Kong
Gastrointestinal Stromal Tumors
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
The goal of this Mesylate apatinib versus standard second-line TKI in the treatment of advanced gastrointestinal stromal tumors: a randomized, open, controlled, single-center clinical study is to explore the efficacy and safety…
- Trial name
- NCT05751733
- Testing
- Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Xiangya Hospital of Central South University
Gastrointestinal Neoplasms
A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
This study aims to evaluate the long-term safety and tolerability of velzatinib (GSK6042981) in adults with GIST who have previously received velzatinib in parent study and continue to benefit from the treatment.
- Trial name
- NCT07843641
- Testing
- Velzatinib
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Stromal Tumors
Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments
To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies
- Trial name
- NCT07618377
- Testing
- DCC-2618
- Where
- 2 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
GIST
Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients
The aim of this study is to evaluate the safety and efficacy of lenvatinib in patients with metastatic or advanced GIST who have failed at least imatinib, sunitinib, and regorafenib treatment.
- Trial name
- LONGIST (NCT07096609)
- Testing
- Lenvatinib Capsules
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumor of Stomach, Submucosal Tumor of Stomach
MCB vs EUS-FNA for Preoperative Pathological Evaluation of Gastric SMT
Gastrointestinal stromal tumors (GISTs) are the most common submucosal tumors (SMTs) of the stomach. The 2022 European Society of Oncology ESMO Diagnosis and Treatment Guidelines recommend that GISTs undergo biopsy with a clear…
- Trial name
- NCT06748690
- Testing
- mucosal cutting biopsy, endoscopic ultrasound-guided-fine needle aspiration
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Peking University People's Hospital
Gastrointestinal Stromal Tumors
The Efficacy and Safety of Temozolomide in SDH-deficient GIST
The goal of this clinical trial is to investigate the efficacy and safety of temozolomide in SDH deficiency GIST patients.
- Trial name
- GIST (NCT05661643)
- Testing
- Temozolomide capsule
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Asan Medical Center
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody.
- Conditions
- Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
- Trial name
- NCT06380816
- Testing
- UCB4594
- Where
- 4 sites in United Kingdom
- Volunteers
- 167 people
- Sponsor
- Cancer Research UK
Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Stromal Tumor (GIST)
Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction
This study is a single-center, prospective, single-arm, exploratory clinical study (phase II exploratory trial). No parallel control group was established in the study, and all subjects who met the inclusion criteria underwent a…
- Trial name
- SAVE-GEJ (NCT07550582)
- Testing
- laparoscopic and endoscopic cooperative surgery
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Gastrointestinal Stromal Tumor
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
This phase II trial is studying how well sorafenib works in treating patients with malignant gastrointestinal stromal tumor that progressed during or after previous treatment with imatinib mesylate and sunitinib malate.
- Trial name
- NCT00265798
- Testing
- Sorafenib Tosylate
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
This phase II trial studies the effect of rogaratinib in treating patients with sarcoma with a change in a group of proteins called fibroblast growth factor receptors (FGFRs) or SDH-deficient gastrointestinal stromal tumor…
- Conditions
- Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor, Metastatic Sarcoma
- Trial name
- NCT04595747
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 18 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
GIST
A Study of Olverembatinib in SDH-deficient GIST.
An international multicenter, open, single-arm pivotal registration phase III study to determine the efficacy and safety of olverembatinib in patients with SDH-deficient gastrointestinal stromal tumor (GIST) who have previously…
- Trial name
- NCT06640361
- Testing
- Olverembatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ascentage Pharma Group Inc.
GIST - Gastrointestinal Stromal Tumor, Advanced
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NB003-04 is a phase II/III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of NB003 in patients with gastrointestinal stromal tumors aged 18 years and above (or…
- Trial name
- GISTAR-1 (NCT07379047)
- Testing
- NB003, regorafenib
- Where
- 32 sites in China, South Korea
- Volunteers
- 255 people
- Sponsor
- Ningbo Newbay Technology Development Co., Ltd
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Gastrointestinal Stromal Tumors
GIST Oral Paclitaxel(Liporaxel)
The purpose of this study is to evaluate safety and efficacy of Liporaxel for patients with GIST who failed on prior standard treatments, including imatinib, sunitinib, and regorafenib, and with low P-glycoprotein expression.
- Trial name
- NCT06326346
- Testing
- Liporaxel
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Asan Medical Center
GIST - Gastrointestinal Stromal Tumor, KIT Gene Mutation
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Gastrointestinal stromal tumors (GISTs) are mostly driven by c-kit or PDGFRA mutations, and commonly occur in the stomach and small intestine.
- Trial name
- NCT07559864
- Testing
- physician-selected treatment, Regorafenib + Envafolimab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jian Li